​​Expert interview on two years of legalization of medical cannabis
​Cologne, 14. March 2019 – On the second anniversary of legalization of cannabis for medical purposes, GECA Pharma was interviewed by Germany's largest news channel n-tv on the current situation and developments. Our managing partner, Mr. Alexander Rieg answered the most important questions and gave an outlook on the expected developments in this rapidly growing market. In 2018, more than 95,000 cannabis prescriptions were issued, and the number of patients increased from around 1,000 in March 2017 to more than 15,000 by the end of 2018. It can be assumed that the number of patients will be much higher, as not all patients are recorded and patients of the private healthcare system need to be counted additionally. Currently, medical cannabis is imported from the Netherlands and Canada. The tender procedure for cultivation in Germany is in the final phase. The cultivation lots will be awarded in April 2019 and the first German cannabis harvest is expected to take place by the end of 2020. Germany will continue to depend heavily on imports of flowers and extracts.
Click the picture to see the whole video. (External link)
Media contact
Alexander Rieg
Executive Partner
Tel. +49 (0)221 4230 67 44
E-Mail:a.rieg@geca-pharma.de
​
About GECA Pharma GmbH
GECA Pharma GmbH is a Cologne based start-up in pharmaceutical wholesaling and direct sales of pharmaceuticals and active ingredients. The GDP-certified (Good Distribution Practice) company specializes in the import of high-quality cannabis products. GECA Pharma GmbH has the wholesale license in accordance with § 52a of the German Medicines Act as well as the permission to handle narcotics, and thus fulfills all strict legal requirements for the handling of drugs and narcotics.